Clinician FAQ

No — it is FDA 510(k)-cleared, which is different from FDA-approved. FDA approval (via PMA) requires clinical trials demonstrating safety and efficacy. 510(k) clearance requires demonstrating substantial equivalence to a legally marketed predicate device. Medicinal leeches (product code NRN) received 510(k) clearance — not PMA approval. The cleared indications are: (1) adjunct to healing of graft/flap tissue with venous congestion, and (2) overcoming problems of venous congestion by creating prolonged localized bleeding. As of December 2024, regulatory oversight transferred from CDRH to CBER (Center for Biologics Evaluation and Research).

On-label: Venous congestion in flaps, grafts, and replants (the 510(k)-cleared indication). Off-label: Legal under the practice-of-medicine doctrine. The FDA regulates manufacturers, not clinician prescribing decisions. Off-label use of cleared medical devices is lawful when supported by clinical judgment. However, off-label use requires: (a) explicit informed consent disclosing off-label status, (b) documentation of clinical rationale, and (c) awareness that insurance coverage is unlikely for off-label indications. Common off-label applications include osteoarthritis, chronic venous insufficiency, and thrombophlebitis.

There is no federal certification requirement for leech therapy. No state medical board has established specific licensing for hirudotherapy. However, institutional credentialing is strongly recommended. Most hospitals require demonstration of competency before granting privileges. The C.H.P. (Certified Hirudotherapy Practitioner) credential from the Academy of Hirudotherapy (~200 hours didactic, 100-200 hours clinical, ~$10,000) is the most structured training program available, but it is a private credential — not a government-recognized license. Hospital-based practitioners typically train via institutional protocols and proctored cases.

No state explicitly addresses hirudotherapy in its medical practice act. The applicable rules depend on your license type: MD/DO: Authorized in all 50 states under general medical practice scope. NP: Full practice authority in 26 states + DC; collaborative practice in remaining states. PA: Under physician supervision per state-specific agreements. RN: May apply leeches under physician orders with institutional credentialing and standing orders. ND: Uncertain — licensure varies (~24 states); some ND practice acts may encompass hirudotherapy under naturopathic scope. C.H.P. without clinical license: High legal risk — performing invasive procedures without a healthcare license may constitute practicing medicine without a license.

Minimum documentation should include: (1) clinical indication and rationale (on-label vs off-label), (2) signed informed consent with specific leech therapy disclosures, (3) antibiotic prophylaxis plan documented before treatment, (4) number of leeches applied, anatomical sites, attachment and detachment times, (5) post-procedure monitoring notes including hemoglobin/hematocrit checks, and (6) adverse event documentation if applicable. For off-label use, document the evidence basis for the chosen indication and the patient’s understanding that the use is off-label.

The primary evidence-based indication is venous congestion in microsurgical flaps and replants when surgical revision has failed or is not feasible. Clinical signs warranting consideration: tissue appears blue/purple, capillary refill is brisk (<1 second) suggesting arterial inflow is intact but venous outflow is obstructed, and tissue tension or swelling is present. Reported off-label uses with varying levels of evidence include: salvage of compromised pedicled flaps, periorbital hematoma evacuation, symptomatic knee osteoarthritis (Level I evidence — Michalsen 2003), and chronic venous insufficiency in selected patients.

Dosing depends on the indication and tissue area: Digit replants: 1-2 leeches per digit, applied at intervals reported from every 2 to 12 hours, or on a salvage basis. Free flap salvage: 3-6 leeches applied to the congested area, replaced every 2-8 hours; continue for about 4-10 days until venous neovascularization occurs. Large flaps or severe congestion: The number of leeches is set by the volume of the flap (Herlin 2017). Osteoarthritis (OA): 4-6 leeches per affected joint per session (based on Michalsen protocol). Chronic venous insufficiency: 4-8 leeches along the affected vein per session, multiple sessions over weeks. Maximum documented in literature: up to 20 leeches for severe cases of chronic venous insufficiency.

Microsurgery/replant salvage: serial leech application every 2–8 h for an average overall duration of 4–10 days (Herlin 2017) until venous outflow recovers. Osteoarthritis: Single session of 4-6 leeches; benefit was documented up to 3 months (Michalsen 2003) and up to 6 months (Andereya 2008). Andereya 2008 tested a repeat application after 4 weeks. Chronic venous disease of the lower extremities: typically 3–8 sessions at a frequency of once or twice a week (Baskova and Isakhanyan 2004). Acute thrombophlebitis: 6–8 sessions in the Magomedov (1998) series. Treatment duration should be guided by clinical response, not a fixed protocol.

Overall: 78% tissue salvage rate when leeches are used for venous congestion in microsurgery (Whitaker et al., 2012 systematic review). Key modifiers: salvage rates drop significantly with Aeromonas infection, reinforcing the importance of antibiotic prophylaxis. Reported success rates range from 65% to 85% depending on the clinical situation (Herlin et al., 2017). Earlier initiation of leech therapy correlates with better outcomes.

Each leech ingests 5-10 mL during feeding (up to 60 minutes). Post-detachment oozing from the bite site contributes an additional 30-40 mL over the next 5-6 hours, for a total of 35-50 mL per leech. The passive oozing — caused by hirudin’s anticoagulant effect — is therapeutically important, as it continues to decompress the venous congestion after the leech detaches. In serial microsurgical therapy, cumulative blood loss can be substantial (in one head-and-neck free-flap protocol an average of 215 leeches and 13 units of packed red cells per patient), necessitating hemoglobin monitoring and transfusion readiness.

First-line: Ciprofloxacin 500 mg PO BID or TMP-SMX DS PO BID. Recommended best practice: Combination of both agents (Herlin et al., 2017), given emerging ciprofloxacin resistance. Timing: Begin prophylaxis before the first leech application; continue throughout the treatment course and for 24-48 hours after the last application. Important: Never use first-generation cephalosporins — Aeromonas species have intrinsic resistance. For penicillin-allergic patients, TMP-SMX alone or a fluoroquinolone plus TMP-SMX is preferred. High-volume centers should implement batch-level surveillance cultures of incoming leech shipments.

This is a growing concern. Ciprofloxacin-resistant Aeromonas has been documented after leech therapy, and in one hospital's leech-tank surveillance 6 of 21 isolates were not ciprofloxacin-susceptible (Wilmer et al., 2013). Plasmid-mediated quinolone resistance (PMQR) genes were found in 42% of fluoroquinolone-susceptible Aeromonas isolates from a natural freshwater reservoir (Kosikowska et al., 2022; these were not leech isolates). Multiple cases of ciprofloxacin-resistant Aeromonas infection following leech therapy have been published since 2011 (e.g., Wang 2011; Patel 2013; Giltner 2013; van Alphen 2014). Low-level antimicrobials in the leech gut may select for resistant strains (Beka et al., mBio 2018). Clinical implications: Combination prophylaxis (ciprofloxacin + TMP-SMX) is now recommended over monotherapy. Batch-level antibiotic susceptibility testing of incoming leech shipments is advised for high-volume centers.

Approximately 50% of microsurgical leech therapy patients require blood transfusion (49.75% — Whitaker et al., 2012). This is primarily due to cumulative blood loss from serial application and prolonged post-detachment oozing. Transfusion need rises with the intensity of leeching: in a digit replantation series, leeched digits had a higher incidence and number of transfusions (PMID 30636508), and in a head-and-neck series using an average of 215 leeches per patient, an average of 13 units of packed red cells was required (PMID 12162779). Monitoring protocol: Check CBC/hemoglobin every 4-8 hours during active treatment. Maintain Hgb >7 g/dL (>8 g/dL in patients with cardiovascular disease). Type and screen should be available before initiating therapy. The transfusion risk is substantially lower in outpatient settings (OA, CVI) where single-session protocols are used.

Local reactions are common: 37-75% of patients experience local itching at the bite sites; erythema and mild swelling around the bite wound are also common. These are typically self-limited and can be managed with topical antihistamines or cool compresses. Systemic reactions are rare: True anaphylaxis to leech salivary proteins has been reported only in isolated case reports in the literature. Risk increases with repeated exposure (sensitization to salivary antigens). Precautions: For patients with a history of prior leech exposure, consider a small test application with 30-minute observation before full treatment. Epinephrine should be available in all treatment settings. Patients with known severe allergic diathesis or mast cell disorders require careful risk-benefit assessment.

In most published series: 7-20% infection rate (de Chalain 1996). With prophylaxis: Markedly lower but not zero. Aeromonas isolation fell from 8.5% to none after levofloxacin prophylaxis in one hospital, whereas 11.9% of prophylaxed patients still developed surgical site infection in another cohort (Kruer 2015). Aeromonas bacteria (mainly A. veronii, long reported as A. hydrophila) are obligate symbionts of the leech gut — the infection risk is inherent to the therapy and cannot be eliminated by surface decontamination. Timeline: Infection can present from 24 hours to 26 days post-treatment (most often within the first 10 days). Clinical impact: Whitaker et al. (2012) report ~78% tissue salvage in 277 cases (PMID 22407551). Signs include: purulent drainage, erythema, fever, wound dehiscence, and flap compromise. Treatment requires culture-directed IV antibiotics (typically a carbapenem or fourth-generation cephalosporin for resistant strains).

Three companies hold active FDA 510(k) clearances: 1. Ricarimpex SAS (Eysines, France) — K040187, the original 510(k) clearance (2004). Species: Hirudo medicinalis/verbana. Ricarimpex reported in 2009 that about 70% of its sales went through its U.S. distributor. 2. Biopharm Leeches Ltd (Hendy, Wales, UK) — K132958 (2014). Species: Hirudo medicinalis/verbana. Supplies internationally with U.S. distribution. 3. Carolina Biological Supply Co. (Burlington, NC, USA) — K140907 (2015; CBER crosswalk: BK251218). The only U.S.-based supplier with FDA clearance. Contact your hospital pharmacy or purchasing department to establish a supplier account. Suppliers ship by express courier, typically with next-day delivery.

Temperature: 4-20°C (39-68°F) in the dark per the supplier (Ricarimpex); the Carolina Biological 510(k) K140907 gives 5-10°C (41-50°F), at which leeches survive for weeks, sometimes months. A dedicated refrigerator or another cool, dark place works well. Water: Mineral water, mountain spring water, or distilled water with Hirudo salt, changed at least once a week or when the water becomes cloudy (supplier recommendation). Container: Glass or food-grade plastic with a secure mesh or perforated lid — leeches are escape artists. Light: Dim or indirect light; avoid direct sunlight. Density: No more than 50 leeches per 10-liter container (about 5 per liter). Label containers with receipt date and supplier lot number.

Shelf life: Leeches stored at 5-10°C survive for weeks, sometimes months, though viability decreases over time. Leeches that have recently fed cannot be reused (single-use biological device — must be disposed of as biomedical waste after each patient). Cost: Approximately $18-20 per leech at current U.S. supplier list prices (e.g., $19.95 each for 7-50 leeches and $18.25 each for 51+ at one major supplier), plus shipping; emergency and same-day delivery carry additional fees.

Used medicinal leeches are classified as regulated medical waste (biohazardous/infectious waste). They must not be flushed, released into the environment, or disposed of in regular trash. Disposal protocol: (1) Euthanize by placing the leeches in a fresh 70% alcohol solution, enough to cover them, for 15 minutes. (2) Seal the leeches in a leak-proof plastic bag, place that in a second sealed bag, and put it in a regulated-medical-waste container lined with a red bag (follow local and state rules, which may treat the alcohol solution as hazardous waste). (3) Dispose through your facility’s regulated medical waste stream. The Defense Centers for Public Health-Aberdeen factsheet (FS No. 019-0623, 2023) provides detailed guidance. Environmental note: Release of non-native Hirudo species is illegal in most U.S. jurisdictions and poses ecological risk.

Patients must understand the following risks and expectations: Bleeding: Bite sites will ooze for 4-24 hours after leech detachment (this is expected and therapeutic). Infection: reported in 7-20% of published series, and in 11.9% of patients in one multicenter cohort despite prophylaxis; signs to watch for include increasing redness, warmth, purulent drainage, or fever. Scarring: Each leech bite leaves a permanent Y-shaped scar. Multiple sessions will result in visible permanent marks. Sensation: Most patients report a brief pinching or stinging when the leech first bites, followed by numbness at the site (the anesthetic effect of leech saliva reduces the pain as feeding proceeds). Appearance: Leeches range from 2-10 cm; some patients experience psychological distress. Screen for leech phobia and consider anxiolytics or distraction techniques for anxious patients.

Informed consent must include the following specific disclosures: (1) Nature of the procedure — application of living FDA-cleared medical leeches to the skin. (2) On-label vs off-label status of the intended use. (3) Risks: prolonged bleeding (4-24h), infection including Aeromonas (7-20% in published series; 11.9% despite prophylaxis in one multicenter cohort), scarring, allergic reaction, potential need for blood transfusion (in microsurgical cases). (4) Benefits: relief of venous congestion and tissue salvage (on-label), or the specific anticipated benefit for off-label indication. (5) Alternatives: surgical revision, observation, or other treatment options. (6) Antibiotic prophylaxis plan. (7) The single-use, living biological nature of the device. Template consent forms are available on our Resources page.

Microsurgical/inpatient setting: Hemoglobin/hematocrit every 4-8 hours during active treatment. Flap or replant assessment every 1 hour (color, capillary refill, temperature, turgor). Transfusion threshold: Hgb <7 g/dL (or <8 g/dL with cardiovascular disease). Monitor bite sites for signs of infection for 4 weeks post-treatment. Outpatient setting (OA, CVI): Observe for 30-60 minutes post-detachment. Apply sterile absorbent dressing over bite sites. Instruct patient on dressing changes (every 4-8 hours for the first 24 hours). Provide written discharge instructions including signs of infection, expected bleeding duration, and when to seek emergency care. Schedule follow-up at 48-72 hours and 2 weeks.

Post-detachment oozing for 4-24 hours is expected and therapeutically desirable — it continues to decompress venous congestion. Normal management: Apply absorbent dressings (gauze pads) and change as needed. Do not apply direct pressure unless bleeding is excessive. Concerning bleeding (>24 hours or hemodynamically significant): Apply topical hemostatic agents (topical thrombin, oxidized cellulose, or silver nitrate sticks to individual bite sites). If on anticoagulation, consider dose adjustment in consultation with the prescribing team. Check CBC — persistent oozing may indicate coagulopathy or previously undiagnosed bleeding disorder. Avoid: Cauterization (risk of tissue damage, especially in compromised flaps).

Absolutely not. Medicinal leeches are single-use biological devices. A leech that has fed on one patient must never be applied to another — it may carry the previous patient’s blood and bacteria in its gut, creating a potential bloodborne pathogen transmission risk. Reuse on the same patient is also contraindicated because the leech’s gut bacteria multiply rapidly after feeding. After use, each leech must be euthanized and disposed of as regulated medical waste. This is consistent with FDA device classification and universal precautions for bloodborne pathogen prevention.

The evidence base varies by indication: Osteoarthritis: 5 randomized controlled trials (four in knee osteoarthritis, one in thumb-base osteoarthritis) (the strongest evidence), including the landmark Michalsen 2003 trial (n=51, Annals of Internal Medicine). Consistent demonstration of significant pain reduction and functional improvement. Microsurgery/replant salvage: A systematic review of 277 reported cases (Whitaker et al., 2012) drawn from case reports and case series. No RCTs (ethically difficult — denying treatment to venously congested tissue is not justifiable). Chronic venous insufficiency: Evidence is limited to small, mostly uncontrolled series reporting improvement in leg pain, heaviness, edema and ulcer healing (e.g., Eldor 1998, n=87 post-thrombotic syndrome; Bapat 1998, n=20 varicose ulcers), as summarized in Baskova & Isakhanyan 2004; no randomized trials are established. Pharmacological derivatives: Level I evidence — bivalirudin (a synthetic peptide designed partly on hirudin's C-terminal sequence) was non-inferior for ischemic events with significantly less major bleeding in ACUITY (n=13,819), and reduced net adverse clinical events in HORIZONS-AMI (n=3,602).

Yes — for knee osteoarthritis. Michalsen et al. (2003) published in Annals of Internal Medicine a randomized controlled trial (n=51) comparing a single session of 4-6 leeches to topical diclofenac for symptomatic knee OA. Results showed significantly greater pain reduction at Day 7 (the primary end point; the between-group pain difference was no longer significant afterwards), improved stiffness, and functional improvement on WOMAC scores. This remains the highest-quality direct evidence for whole-leech therapy. Additional RCTs (Andereya 2008, Stange 2012) and a meta-analysis (Lauche 2014) are consistent with these findings. For microsurgical indications, Level I evidence does not exist (and may not be ethically obtainable), but systematic reviews of large case series provide Level III-IV evidence supporting efficacy.

Leech-derived compounds have achieved the highest level of clinical evidence in medicine. Bivalirudin (Angiomax) — a synthetic analog of hirudin (the leech’s anticoagulant) — was validated in two landmark megatrials: ACUITY (n=13,819; Stone et al., NEJM 2006) demonstrating non-inferior efficacy with reduced bleeding vs heparin+GP IIb/IIIa inhibitors in ACS, and HORIZONS-AMI (n=3,602; Stone et al., NEJM 2008) showing reduced cardiac mortality (1.8% vs 2.9%) and major bleeding in primary PCI. These represent the most solid evidence that leech biology has produced clinically significant therapeutics.

Key research priorities include: 1. RCTs for off-label indications: Chronic venous insufficiency, thrombophlebitis, and post-thrombotic syndrome lack randomized trial data. 2. Antibiotic resistance surveillance: Systematic monitoring of Aeromonas susceptibility patterns across leech suppliers — no standardized protocol exists. 3. Optimal dosing: No rigorous dose-finding studies for any indication; current protocols are empirically derived. 4. Long-term outcomes: Most microsurgery studies report short-term salvage; 5-10 year functional outcomes are rarely documented. 5. Cost-effectiveness: No formal health economic analyses comparing leech therapy to alternative treatments. 6. Salivary proteomics: Identified proteins with largely uncharacterized clinical potential (Babenko et al., 2020).